Introduction {#S1}
============

There is a revived optimism despite many challenges in drug discovery and development (DDD) \[[@R1]--[@R3]\]. DDD educational programs can influence growth and development of novel therapies and market transition \[[@R4]\]. Due to escalating complexity and feasibility barriers, there is a significant need for DDD educational programs. The median cost and time to develop a potential molecule from its discovery to approval is 2.6 billion dollars and 36 years, respectively \[[@R5],[@R6]\]. Only 10 to 20% of health-related research projects reach human trials; only 6% of drugs that enter phase I trials reach approval status \[[@R7],[@R8]\]. The new drug approval rate has remained low \[[@R9],[@R10]\]. Therefore, to promote successful translation in DDD, scientists need skills and training \[[@R11]\]. Few DDD training programs integrate aspects on both discovery and development and expose students to opportunities and experts in the field \[[@R12]\].

In September 2012 with funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), we began enrollment for the Drug Development Educational Program (DDEP) at New York University (NYU). We aim to teach graduate and postgraduate students the essentials of DDD and inspire these motivated and talented individuals to get more involved in the translation of scientific discoveries and enter the DDD workforce as trained scientists, engineers, business analysts, and entrepreneurs. This improved, informed DDD workforce will be better equipped to address the nation's biomedical and clinical research needs.

Our educational objectives were met, consistent with reported data from our two-year analysis \[[@R13]\]. Furthermore, we explored *why* students enrolled in each course, *what* they learned, and the course's relevance to their career goals. We also traced the career paths of students who received DDEP's career development awards. DDEP aims to teach essential skills and is the only known program of its kind within the Clinical and Translational Science Institutes (CTSIs).

Materials and methods {#S2}
=====================

Description of course series {#S3}
----------------------------

The NYUSOM DDEP was created in 2012 with support from NIDDK. Currently in its sixth year, the DDEP was initially comprised of a two-course series designed to highlight the essential and innovative features of the DDD process. Our goals are: 1) to teach a new generation of multidisciplinary students at the graduate and post-graduate levels about DDD; 2) to potentiate and expedite the translation of therapeutics and other applications, both novel and repurposed; and 3) to bridge the translational gap.

Enrollment is open to all NYU graduate and post-graduate students. The first course of the two-course series is Drug Development in a New Era (DDNE). This course is held in the fall term and focuses on the post-compounding aspects of DDD such as intellectual property, regulatory aspects, and marketing. The spring term course, Molecular Signaling in the Discovery and Development of Therapeutics (MSDDT), expands on molecular signaling pathways as potential sites for drug targets as well as viability testing ([Table 1](#T1){ref-type="table"}). Each course grants three credits. Classes are two hours in duration, where each begins with a lecture given by an expert in the field followed by an interactive discussion. Students are required to arrive prepared, having completed the assigned reading and coursework.

DDNE (fall) course {#S4}
------------------

The goal of the DDNE course is to provide an overview of the regulatory, economic, ethical, and business aspects of DDD from the preclinical phase through post-approval marketing and monitoring. Students are exposed to a wide range of topics including protocol planning, safety monitoring, cost and pricing analysis, and intellectual property. Students also learn how basic and clinical sciences, statistical analysis, business management, legal, and marketing departments converge in this interdependent, multidisciplinary process. At the end of the term, students are required to complete a final project that entails submission of a "mini" Investigational New Drug Application (IND) \[[@R7]\].

MSDDT (spring) course {#S5}
---------------------

In the MSDDT course, the principles of discovering and developing therapeutics in the lab as well as essential signaling pathways such as RAS and AKT are explored. Students learn about entity-specific paradigms that can help predict successful DDD trajectories and how to plan target selection via experimental testing. To ensure students are ready for the different scientific aspects of DDD, students are exposed to topics such as developing receptor and pathway networks, prediction models, new technologies, and challenges of designing animal models and clinical trials. Students are required to submit a final paper on research methods or approaches used to design therapy \[[@R8]\].

Student demographics {#S6}
--------------------

Demographic information, training level, and graduate school affiliation was collected from students who enrolled between Fall 2012 and Spring 2017.

Program evaluation {#S7}
------------------

### Pre/Post course surveys and analysis {#S8}

To evaluate students' self-reported contextual knowledge, each student completed a pre course survey on the first day of the course and a post course survey on the last day of the course. The surveys asked students to rate how well they understood each of the topics/knowledge items. The response options were: (1) nothing, (2) almost nothing, (3) some and (4) a great deal. Responses to all knowledge questions were summed to create a total knowledge score. Each survey also included a question about the relevance of the course in terms of career goals. The choices were: (1) not at all relevant, (2) only a little relevant, (3) somewhat relevant and (4) very relevant. IBM SPSS was used to analyze the differences between the pre and post course surveys. Due to small sample size and non-normally distributed data, Wilcoxon Ranked Sum Test was used for all data analyses.

### Lecture ratings {#S9}

On the last day of each course, students received surveys asking them to rate each of the lectures in 4 different domains: content, presentation, relevance, and overall. The options for each response were: (1) poor, (2) lower than expected, (3) satisfactory, (4) above expectations, (5) superior. The response to the question "Was the lecture free of commercial bias?" was also analyzed.

### Free-response text {#S10}

To capture more qualitative information, each survey contained free-response questions. In the pre course survey, students were asked, "What are the main things you hope to get out of this course?" They were also asked to explain their rating for the career relevance question. In the post course survey, students were asked, "What are the main take home points you got out of this course?"

IBM SPSS Text Analytics for Surveys was used to analyze the answers to free--response questions. The responses were grouped into categories for query and associated with keywords the students utilized in the response. We manually excluded words that contained components of search terms. Likewise, some responses that were not automatically grouped into the corresponding categories were grouped manually based on content. For the questions "What are the main things you hope to get out of this course" and "What are the main take home points you got out of this course", Chi-square test was used to compare the differences between the pre and post course surveys.

### Career development award {#S11}

Enrolled students were eligible for a career development award. The goal of the award was to provide support for students to pursue activities to advance their careers. Uses included tuition remission, workshops, course/conference attendance, and publication support. Online search and telephone follow-up were used to track recipient's career trajectories.

Results {#S12}
=======

Student demographics {#S13}
--------------------

From September 2012 through June 2017, 139 students completed the DDNE course, and 75 students completed the MSDDT course. A total of 196 students completed at least one course in the DDEP; 18 (9%) students completed both DDNE and MSDDT.

DDNE (fall) course {#S14}
------------------

The 139 DDNE students were comprised as such: 48 (35%) postdoctoral PhD, 30 (22%) PhD or MD/PhD candidate, 29 (21%) MD/Masters of Science in Clinical Investigation dual-degree candidate (MD/MSCI), 14 (10%) other Master's degree candidate, 11 (8%) post-doctoral MD, and 7 (5%) faculty. 90 students (65%) were either enrolled or held positions at NYUSOM, 29 (21%) at NYU Sackler Institute of Graduate Biomedical Sciences, 7 (5%) at NYU Tandon School of Engineering, 5 (4%) at NYU Graduate School of Arts and Sciences (GSAS), 4 (3%) at NYU Stern School of Business, 3 (2%) at NYU College of Dentistry, and 1 (1%) at NYU Steinhardt School of Culture, Education, and Human Development ([Figure 1](#F1){ref-type="fig"}).

MSDDT (spring) course {#S15}
---------------------

The 75 students who completed the MSDDT course were comprised as such: 39 (52%) PhD or MD/PhD candidate, 29 (39%) post-doctoral PhD, 4 (5%) Master degree candidate, and 3 (4%) post-doctoral MD. 41 students (55%) were either enrolled or held positions from NYU Sackler, 27 (36%) from NYUSOM, 3 (4%) from NYU Tandon, 2 (3%) from NYU GSAS, and 2 (3%) from NYU Dentistry ([Figure 1](#F1){ref-type="fig"}).

Program evaluation {#S16}
------------------

### DDNE (fall) course {#S17}

#### Pre/Post course surveys {#S18}

139 students completed DDNE between September 2012 and June 2017. Of those, 127 (91%) completed the pre course survey, 98 (71%) completed a post course survey, and 89 (64%) completed both pre and post course surveys. Responses to all the individual knowledge questions, the total knowledge score, and the career relevance question were not normally distributed (pre course total knowledge score: Kolmogorov-Smirnov p = 0.006 and Shapiro-Wilk p = 0.114; all others: Kolmogorov-Smirnov p ≤ 0.001 and Shapiro-Wilk p ≤ 0.001). Students rated themselves significantly higher in each of the knowledge areas as well as overall knowledge after taking the course. The mean pre course career relevance (3.59 ± 0.57) was not different from the post course career relevance (3.51 ± 0.62) (Z=−0.480; p = 0.631) ([Figure 2A](#F2){ref-type="fig"}, [Table 2](#T2){ref-type="table"}).

#### Lecture ratings {#S19}

94 (68%) students completed the lecture ratings (Range 1-5). The mean ratings for each domain were: content 4.17 (±0.80), presentation 4.12 (±0.87), relevance 4.25 (±0.81), and overall 4.18 (±0.81). 95% (1062 of 1116 responses to all lectures) reported that lectures were free of commercial bias.

#### Free response text {#S20}

113 (89%) of the 127 students who completed the pre course survey explained their career relevance ratings. 66 (58% of the 113 responses with explanations) indicated interest in working in research and DDD related careers. 40 (35%) indicated interest in a career outside academia ([Table 3](#T3){ref-type="table"}).

In the pre course survey, 94 (74% of the 127 responses) students responded to the question "what they hope to get out of the class." 35 (37% of the 94 responses to this question) indicated they were interested in the business and/or marketing aspects of DDD, 14 (15%) were interested in learning about the regulatory aspects, and 1 (1%) indicated interest in intellectual property ([Table 4](#T4){ref-type="table"}). In the post course survey, 92 (94% of the 98 responses) students answered, "what were the main takeaways of the class." 31 students (34% of the 92 responses to this question) indicated they learned about the business and marketing aspects of DDD, 20 (22%) said they learned about regulatory aspects, and 13 (14%) learned about intellectual property. In the post course surveys, there is a significant increase (χ^2^ p = 0.034) in the number of responses that include keywords in the intellectual property category ([Table 4](#T4){ref-type="table"}).

### MSDDT (spring) course {#S21}

#### Pre/Post course surveys {#S22}

75 students completed the MSDDT course over five years, 68 (91%) completed the pre course survey, 52 (69%) completed a post course survey, and 46 (61%) completed both pre and post course surveys. Responses to all the individual knowledge questions, the total knowledge score, and the career relevance question were not normally distributed (pre course total knowledge: Kolmogorov-Smirnov p = 0.004 and Shapiro-Wilk p = 0.005; post course total knowledge: Kolmogorov-Smirnov p = 0.004 and Shapiro-Wilk p = 0.226; all the others: Kolmogorov-Smirnov p ≤ 0.001 and Shapiro-Wilk p ≤ 0.001). As was the case in DDNE, students rated themselves significantly higher in each of the knowledge areas as well as total knowledge score after taking the course. Similarly, there was no difference between the pre and post course career relevance ratings (pre course: 3.64 ± 0.55; post course: 3.40 ± 0.85; Z = −1.206, p = 0.228) ([Figure 2B](#F2){ref-type="fig"}, [Table 2](#T2){ref-type="table"}).

#### Lecture ratings {#S23}

51 (68%) students in the MSDDT course completed the lecture ratings (Range 1-5). The mean ratings for each domain were: content 3.96 (±0.85), presentation 3.95 (±0.92), relevance 4.06 (±0.85), and overall 4.01 (±0.88). 98% (489 of 498 responses to all lectures) of responses reported that lectures were free of commercial bias.

#### Free response text {#S24}

55 (81%) of the 68 students who completed the pre course survey explained their career relevance ratings. A majority of responses (37, 67% of the 55 responses with explanations) indicated interest in working in research and DDD related careers. 17 (31%) students indicated interest in a career outside academia ([Table 3](#T3){ref-type="table"}).

In the pre course survey, 63 (93% of the 68 responses) responded to the question, "what they hope to get out of the class." 32 (51% of the 63 responses to this question) indicated they were interested in learning how to discover a drug, 9 (14%) were interested in the business and/or marketing aspects of DDD, 2 (3%) were interested in learning about the regulatory aspects ([Table 4](#T4){ref-type="table"}). In the post course survey, 47 (90% of the 52 responses) students answered "what were the main takeaways of the class." 24 (51% of the 47 responses to this question) students indicated they learned how to discover a drug, 9 (19%) learned about the business and marketing aspects of DDD, 3 (6%) learned about regulatory aspects, and 1 (2%) learned about intellectual property ([Table 4](#T4){ref-type="table"}).

Career development award {#S25}
------------------------

26 students were granted funds for career development activities. A total of \$92,250 was awarded. 8 (31%) awardees were PhD candidates, 7 (27%) post-doctoral PhDs, 5 (19%) MD/MSCI candidates, 4 (15%) post-doctoral MDs, and 2 (8%) were Master's degree candidates. 19 (73%) of the award recipients were women. 6 (23%) of the awardees were under-represented minorities (URM). 16 (62%) of the students used the funds to attend conferences, 9 (35%) for partial tuition remission, 4 (15%) for grant writing workshops, 2 (8%) to enroll in mini-courses, and 1 (4%) for publication support ([Figure 3](#F3){ref-type="fig"}).

Where are the students who received career development support after graduation from their primary matriculated program/appointment? {#S26}
------------------------------------------------------------------------------------------------------------------------------------

The five graduated medical students who received support are all currently enrolled in US residency programs. Two of the eight PhD students are now graduated; one has a position as a post-doctoral trainee and one is a consultant at a healthcare company. Two Master's degree students graduated; one is a project coordinator at a healthcare company and the other is a clinical trials research coordinator. All four post-doctoral MD students are now assistant professors at academic institutions. One of the seven post-doctoral PhD students is a manager at a pharmaceutical company; the other six continue their post-doctoral training ([Table 5](#T5){ref-type="table"}).

Discussion {#S27}
==========

Our program continues to attract talented and motivated students from a variety of backgrounds at an early career stage. Initially, enrollment included students from Schools of Medicine, Biomedical Sciences, and Arts and Sciences. Currently, the student base has expanded to include the Schools of Dentistry, Engineering, Business, and Education. Moreover, our lecturers have diverse, yet specific, expertise from the various realms of DDD including academia, government/regulatory agencies, industry (large and small), and the business/economic sector. As a result, the lectures and discussions provide a platform for the multidisciplinary students to exchange ideas and share experiences toward a common goal.

The students who received career development awards are arguably our most enthusiastic students. Funds were used most often for conference attendance, which shows that recipients have strong interests in networking and becoming more fluent in their field of interest. Some of these awardees have embarked on careers in competitive medical fields and others are directly involved in DDD. It has been shown that MD/MSCI students apply to more competitive residency programs, and the current institutions and specialties of our MD/MSCI graduate recipients reflect this tendency \[[@R9]\]. Our program is successful in preparing these students to be key players in DDD. In addition, our career development funding encourages URM students. 23% of our recipients are URMs, while only 8.3% of all science, technology, engineering and mathematics PhDs are URMs \[[@R10]\]. Likewise, women have historically been underrepresented in science and industry but 73% of our career development recipients are women \[[@R11]\].

In the first two years, there were 37 and 23 students in DDNE and MSDDT, respectively \[[@R6]\]. After five years, these numbers have increased to 139 and 75, respectively, reflecting increased annual enrollment in both courses without compromising the quality of lectures and discussions. With a larger sample size, we found consistently high lecture ratings in both courses, and students demonstrated learning in all areas queried. The high post course survey knowledge ratings suggest that our course can give students the knowledge, networking abilities, and confidence needed to successfully participate in DDD projects. In addition to gained knowledge, we can ascertain from the free text responses to "what students got out of the course" that students learned about the regulatory, business, economic, marketing, and intellectual property aspects. Furthermore, in regards to the latter, the number of responses that contained the keyword intellectual property increased significantly in the post-course DDNE survey. This is likely due to the course's highly rated lecture on intellectual property \[[@R14]--[@R19]\].

Regarding career relevance, the majority of students (58% DDNE, 67% MSDDT) stated a desire to pursue a research and/or DDD related career. Approximately 1/3 of students indicated interest in working outside academia. Current trends in PhD training programs show that only 12.8% of graduates ultimately end up in academic careers \[[@R12]\]. Additional educational programs such the DDEP are important programs to enable students to gain skills and potentiate the DDD workforce.

The authors acknowledge that since there are no final exams (post-test) in our course series (and we did not administer a pre-test), we do not have a quantitative measurement of knowledge gained. The career trajectories of only those students who received the career development awards were examined.

Conclusion {#S28}
==========

Our DDEP program is successful in teaching DDD to students at an early career stage. Despite the fact that our students are at different levels of training and from different schools/fields, the material is appropriate and relevant. By inviting speakers from different areas of DDD and maintaining a discussion-based forum with multidisciplinary students, our program is able to provide collaborative, yet efficient training. We hope to produce highly trained scientists, engineers, educators, business analysts, and other innovators in DDD to further fuel the process. We will continue to expand the program. The next expansion will include an additional course, Biotechnology Industry: Structure and Strategy. The NYU Drug Development Educational Program serves as a framework for other institutions to develop similar, compatible programs to train early stage researchers in this critical area.
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![Student demographics\
This bar graph shows the student demographic data: enrollment numbers, training levels, and affiliated schools for both DDNE and MSDDT courses.](nihms953279f1){#F1}

![Pre and post course survey results. (A) This figure shows the results of the pre and post course surveys for the DDNE Course. (B) This figure shows the results for the MSDDT Course. The survey choices were (1) nothing, (2) almost nothing, (3) some, and (4) a great deal. The mean ratings and standard deviations are shown. Students rated themselves to be more knowledgeable in all areas after taking both the DDNE and MSDDT courses respectively (p \< 0.001). There is no statistical difference in career relevance for either course.](nihms953279f2){#F2}

![Career development award recipients\
This bar graph displays the number of career development awardees categorized by gender, training level, underrepresented minority status, and purpose of use. Of note is that some students used career development funds for more than one purpose.](nihms953279f3){#F3}

###### 

Lecture topics.

  Drug Development in a New Era (DDNE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Big Data, Supercomputing, Artificial IntelligenceBiostatistics and Study Design: New Statistical Approaches and the Application to New Drug Targets Including Metabolic Syndrome/ObesityBiotechnology/Entrepreneurship in ScienceBrown Adipogenesis as a Target for New Diabetes DrugsChallenges in Drug Discovery for the Treatment of Diabetic ComplicationsClinical TrialsCase Study: Finding FibromyalgiaDe-orphanization of GPCRs and Ligand IdentificationEpigenetic Basis of Metabolic Syndrome and Prenatal Environmental Exposures and Design of Translational Animal Models to Bridge Biomarkers from Mouse to Man and Targeted Drug Selection PredictionFinding the Missing Heritability Wide-Locus GWAS in PharmacogenomicsFraud and MisconductGenomic Medicine and Repurposing of DrugsHealthcare in the New EconomyHuman Subject Protection in ResearchInfliximab: How a TNF Inhibitor Advanced from Modest Beginnings to Unforeseen Therapeutic Success   Intellectual Property Relating to Clinical Data in Drug DevelopmentModifiers of Gene Expression in Genetic Disease and Measuring Effects on PhenotypeDrug Development in Orphan DiseaseLysosomal Storage Disorders: Novel TherapeuticsEthics in Clinical Trials, FDA and Conflicts of Interest, PDUFAMoving from Big Data to Better Models of Disease and Drug ResponseNew Diabetes and Obesity Drugs and the FDA, Industry Drug DevelopmentNext Generation Data Mining in PharmacogenomicsPatenting Clinical DataPharmaco-kid-netics: Pediatric Drug Development, an Industry PerspectivePharmacovigilance in Drug Safety, Application of Statistical Data Mining Techniques to Monitor and Predict Drug SafetyPhase I/II Developmental TrialsRepurposing Failed Drugs to Create Successful Medicines in Women's HealthDrug Discovery and Development: From Target to IND and NDA
  Molecular Signaling in the Development and Discovery of Therapeutics (MSDDT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Targeting the PI3k-Akt-mTOR PathwayTargeting Metabolic Disease -- Primary Efficacy Endpoints for Cardiometabolic TrialsStructured-Base Drug/Vaccine Design Targeting HIV/AIDSStartup Biotech: a First Person Perspective on the Risks and Rewards of Starting Your Own CompanySignaling Transduction and Signal Management in PharmacovigilanceRNAi for Drug DiscoveryReceptors and Drug Binding, Pharmacology of Autonomic Nervous SystemRas/CancerRAGE and Diabetic Complications and Therapeutics ApproachesProtein Kinases as Targets for Drug DevelopmentPrinciples of G Protein Coupled Receptor signalingPreventative CardiologyPharmacology of AddictionPersonalized MedicineOpioid Receptor Heterodimerization in Analgesia and AddictionNuclear Hormone ReceptorsNeuronal Control of Eating BehaviorMolecular Signatures DiseaseMetabolism and Cancer                                                                                                          Medicinal ChemistryImmunotherapy for TauopathiesGlycosaminoglycan Modulation of Signaling Pathways: Implications for Drug DevelopmentDrug Distribution, Kinetics, Metabolism, and Cytochrome P450sDrug Addiction: Insights Obtained from Basic Science ResearchDiscovery and Rational Development of an Antagonist to Phosphaturic TumorsDiscovery and Rational Development of an FGF23 Hormone AntagonistDiabetic Neuropathy trials and Choice of EndpointsDiabetes and ObesityComputational Drug DiscoveryBivalent Approaches to Drug DiscoveryApproaches and Consideration for Biologic Therapeutic Development -- Targeting the FGF PathwayAldose Reductase and Diabetes ComplicationsAdenosine ReceptorImmunomodulators: Discussion between Developer and Industry PartnerMacrocyclic Kinase Inhibitors

Abbreviations (in alphabetical order): Acquired Immunodeficiency Syndrome (AIDS), Fibroblast Growth Factor (FGF), Food and Drug Administration (FDA), G-Protein-Coupled Receptor (GPCR), Genome-wide association study (GWAS), Human Immunodeficiency Virus (HIV), Investigational New Drug (IND), Mechanistic Target of Rapamycin (mTOR), New Drug Application (NDA), Pharmacokinetics (PK), Phosphoinositide 3-kinase(PI3k), Prescription Drug User Fee Act (PDUFA), Protein Kinase B (Akt), Receptor for Advanced Glycation End Product (RAGE), RNA interference (RNAi), Tissue Necrosis Factor (TNF).

###### 

Pre-course and post course surveys results. Abbreviation: Standard Deviation (SD)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug Development in a New Era (DDNE)                                                                                                                                                                                     
  ------------------------------------------------------------------------------ ------------------ ------------------- ----------------- ----------------------------------- -------------------------------------------- ---------
  Knowledge Question                                                                                2.57\               3.59\             1.02                                −7.795                                       \<0.001
                                                                                                    (0.79)              (0.43)                                                                                             

  2                                                                              2.41\              3.76\               1.35              −7.248                              \<0.001                                      
                                                                                 (0.72)             (0.52)                                                                                                                 

  3                                                                              2.23\              3.71\               1.48              −7.886                              \<0.001                                      
                                                                                 (0.73)             (0.46)                                                                                                                 

  4                                                                              2.61\              3.65\               1.04              −7.282                              \<0.001                                      
                                                                                 (0.73)             (0.52)                                                                                                                 

  5                                                                              2.39\              3.35\               0.96              −6.801                              \<0.001                                      
                                                                                 (0.69)             (0.58)                                                                                                                 

  6                                                                              1.91\              3.22\               1.31              −7.496                              \<0.001                                      
                                                                                 (0.75)             (0.56)                                                                                                                 

  7                                                                              2.03\              3.58\               1.55              −7.786                              \<0.001                                      
                                                                                 (0.82)             (0.5)                                                                                                                  

  Total Knowledge Score                                                          16.13\             24.69\              8.56              −8.099                              \<0.001                                      
                                                                                 (3.64)             (2.33)                                                                                                                 

  Career Relevance                                                               3.59\              3.51\               −0.08             −0.480                              0.631                                        
                                                                                 (0.57)             (0.62)                                                                                                                 

  Molecular Signaling in the Development and Discovery of Therapeutics (MSDDT)                                                                                                                                             

  Question                                                                       Pre Course Mean\   Post Course Mean\   Mean Difference   Wilcoxon Signed Rank Test Z-Score   Wilcoxon Signed Rank Test Significance (p)   
                                                                                 (SD)               (SD)                                                                                                                   

  Knowledge Question                                                                                2.07\               3.15\             1.08                                −5.078                                       \<0.001
                                                                                                    (0.82)              (0.57)                                                                                             

  2                                                                              2.16\              3.35\               1.19              −5.116                              \<0.001                                      
                                                                                 (0.80)             (0.68)                                                                                                                 

  3                                                                              2.27\              3.27\               1.00              −4.824                              \<0.001                                      
                                                                                 (0.79)             (0.57)                                                                                                                 

  4                                                                              2.10\              3.38\               1.28              −5.182                              \<0.001                                      
                                                                                 (0.82)             (0.63)                                                                                                                 

  5                                                                              2.56\              3.46\               0.90              −4.885                              \<0.001                                      
                                                                                 (0.72)             (0.61)                                                                                                                 

  6                                                                              2.31\              3.08\               0.77              −4.098                              \<0.001                                      
                                                                                 (0.84)             (0.57)                                                                                                                 

  7                                                                              1.93\              3.00\               1.07              −5.232                              \<0.001                                      
                                                                                 (0.75)             (0.66)                                                                                                                 

  8                                                                              2.09\              3.23\               1.14              −5.114                              \<0.001                                      
                                                                                 (0.77)             (0.58)                                                                                                                 

  Total Knowledge Score                                                          16.47\             25.15\              8.68              −5.757                              \<0.001                                      
                                                                                 (5.44)             (3.32)                                                                                                                 

  Career Relevance                                                               3.64\              3.40\               −0.24             −1.206                              0.228                                        
                                                                                 (0.55)             (0.85)                                                                                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Free text responses -- Career Relevance Question.

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug Development in a New Era (DDNE)                                                                    
  ------------------------------------------------------------------------------------------------------- ----------------------------------------------
  Number of Pre Course Surveys Completed                                                                  127 (91%)[\*](#TFN2){ref-type="table-fn"}

  Number of Students Answered the Career Relevance Free Text Question                                     113 (89%)[\*\*](#TFN3){ref-type="table-fn"}

  Categorized Answers                                                                                     

  Number of students indicated interest in career **outside academia**\                                   40 (35%[\*\*\*](#TFN4){ref-type="table-fn"})
  *(keywords: biotech, industry, company, pharma, consulting, biotechnology, pharmaceutical, business)*   

  Number of students indicated interest in working for **research and DDD related careers**\              66 (58%[\*\*\*](#TFN4){ref-type="table-fn"})
  *(keywords: research, drug development, clinical trials, basic science)*                                

  Molecular Signaling in the Development and Discovery of Therapeutics (MSDDT)                            

  Total Enrollment                                                                                        75

  Number of Pre Course Surveys Completed                                                                  68 (91%[\*](#TFN2){ref-type="table-fn"})

  Number of Students Answered the Career Relevance Free Text Question                                     55 (81%[\*\*](#TFN3){ref-type="table-fn"})

  Categorized Answers                                                                                     

  Number of students indicated interest in career **outside academia**\                                   17 (31%[\*\*\*](#TFN4){ref-type="table-fn"})
  *(keywords: biotech, industry, company, pharma, consulting, biotechnology, pharmaceutical, business)*   

  Number of students indicated interest in working for **research and DDD related careers**\              37 (67%[\*\*\*](#TFN4){ref-type="table-fn"})
  *(keywords: research, drug development, clinical trials, basic science)*                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------

\% of students who completed the course;

\% of students who completed the survey;

\% of students who answered the free response question).

Abbreviations: Chi-square (X^2^), Drug Discovery and Development (DDD), New Drug Application (NDA), Investigational New Drug (IND), Intellectual Property (IP)

###### 

Free response question -- What Students Hope to Get Out of the Class (Pre-Course) and What They Got Out of the Class (Post Course).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug Development in a New Era (DDNE)                                                                                                                                         
  ----------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- ----------------------------------------------
  Type of Survey                                                                                                                Pre Course                                     Post Course

  Number of Surveys Completed                                                                                                   127 (91%[\*](#TFN6){ref-type="table-fn"})      98 (71%[\*](#TFN6){ref-type="table-fn"})

  Number of Students Answered the Free Text Question                                                                            94 (74%[\*\*](#TFN7){ref-type="table-fn"})     92 (94%[\*\*](#TFN7){ref-type="table-fn"})

  Categorized Answers                                                                                                                                                          

  Type of Survey                                                                                                                Pre Course                                     Post Course

  Number of students *wanted to learn/learned* the **business and marketing** aspects of DDD\                                   35 (37%[\*\*\*](#TFN8){ref-type="table-fn"})   31 (34%[\*\*\*](#TFN8){ref-type="table-fn"})
  *(keywords: property, business, industry, entrepreneur, startup, market, biotech, pharma)*\                                                                                  
  X^2^ p-Value = 0.884                                                                                                                                                         

  Number of students *wanted to learn/learned* **regulatory aspects of** DDD\                                                   14 (15%[\*\*\*](#TFN8){ref-type="table-fn"})   20 (22%[\*\*\*](#TFN8){ref-type="table-fn"})
  *(keywords: regulatory, regulation, approve, approval, FDA, NDA, IND)*\                                                                                                      
  X^2^ p-Value = 0.178                                                                                                                                                         

  Number of students *wanted to learn/learned* about **intellectual property**\                                                 1\                                             13\
  *(keywords: IP, protect, intellectual, property, patent)*\                                                                    (1%[\*\*\*](#TFN8){ref-type="table-fn"})       (14%[\*\*\*](#TFN8){ref-type="table-fn"})
  X^2^ p-Value = 0.034                                                                                                                                                         

  Molecular Signaling in the Development and Discovery of Therapeutics (MSDDT)                                                                                                 

  Total Enrollment                                                                                                              75                                             

  Type of Survey                                                                                                                Pre Course                                     Post Course

  Number of Surveys Completed                                                                                                   68 (91%[\*](#TFN6){ref-type="table-fn"})       52 (69%[\*](#TFN6){ref-type="table-fn"})

  Number of Students Answered the Free Text Question                                                                            63 (93%[\*\*](#TFN7){ref-type="table-fn"})     47 (90%[\*\*](#TFN7){ref-type="table-fn"})

  Categorized Answers                                                                                                                                                          

  Type of Survey                                                                                                                Pre Course                                     Post Course

  Number of students *wanted to learn/learned* how to **discover a drug** *(key words: inhibit, pathway, target, discovery)*\   32 (51%[\*\*\*](#TFN8){ref-type="table-fn"})   24\
  X^2^ p-Value = 1.000                                                                                                                                                         (51%[\*\*\*](#TFN8){ref-type="table-fn"})

  Number of students *wanted to learn/learned* the **business and marketing** aspects of DDD\                                   9\                                             9\
  *(keywords: property, business, industry, entrepreneur, startup, market, biotech, pharma)*\                                   (14%[\*\*\*](#TFN8){ref-type="table-fn"})      (19%[\*\*\*](#TFN8){ref-type="table-fn"})
  X^2^ p-Value = 0.132                                                                                                                                                         

  Number of students *wanted to learn/learned* **regulatory aspects of** DDD\                                                   2\                                             3\
  *(keywords: regulatory, regulation, approve, approval, FDA, NDA, IND)*\                                                       (3%[\*\*\*](#TFN8){ref-type="table-fn"})       (6%[\*\*\*](#TFN8){ref-type="table-fn"})
  X^2^ p-Value = 0.317                                                                                                                                                         

  Number of students *wanted to learn/learned* about **intellectual property**\                                                 0\                                             1\
  *(keywords: IP, protect, intellectual, property, patent)*\                                                                    (0%[\*\*\*](#TFN8){ref-type="table-fn"})       (2%[\*\*\*](#TFN8){ref-type="table-fn"})
  X^2^ p-Value = 0.317                                                                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\% of students who completed the course;

\% of students who completed the survey;

\% of students who answered the free response question).

Abbreviations: Chi-square (X2), Drug Discovery and Development (DDD), New Drug Application (NDA), Investigational New Drug (IND), Intellectual Property (IP)

###### 

Current fields and disciplines of graduated students who received career development funds.

  MD/MSCI Dual Degree Candidates                                                                                                                                                
  -------------------------------- --------------------- -------------------- ------------------------------------- ----------------------------------------------------------- --------------------------------------------------------------------
  1                                2013                  2014                 Resident                              Radiology                                                   NYUSOM, NY, NY
  2                                2014                  2015                 Resident                              Radiology                                                   Perelman SOM at the University of Pennsylvania, Philadelphia, PA
  3                                2014                  2015                 Resident                              Pediatrics                                                  Mount Sinai SOM, NY, NY
  4                                2015                  2015                 Resident                              Dermatology                                                 NYUSOM, NY, NY
  5                                2016                  2017                 Resident                              Ophthalmology                                               Johns Hopkins SOM, Baltimore, MD
  PhD Candidates                                                                                                                                                                
  Index                            Year Received Award   Year of Graduation   Position                              Department                                                  Institution
  6                                2016                  2016                 Post-doctoral fellow                  Cardiothoracic surgery                                      Weill Cornell Medical College, NY, NY
  7                                2016                  2016                 Consultant                            N/A                                                         ClearView Healthcare Partners (healthcare/consulting) Boston, MA
  Masters Degree Candidates                                                                                                                                                     
  Index                            Year Received Award   Year of Graduation   Position                              Department                                                  Institution
  8                                2013                  2014                 Senior Clinical Project Coordinator   N/A                                                         QuintilesIMS (healthcare/technology/consulting), Overland Park, KS
  9                                2016                  2017                 Clinical Trial Research Coordinator   N/A                                                         NYU Dental School, NY, NY
  Post-Doctoral MDs                                                                                                                                                             
  Index                            Year Received Award   Year of Graduation   Position                              Department                                                  Institution
  10                               2013                  2012                 Assistant Professor                   Internal Medicine/Preventative Medicine/Tropical Medicine   Weill Cornell Medical College, NY, NY
  11                               2013                  2003                 Assistant Professor                   Neurology                                                   NYUSOM, NY, NY
  12                               2014                  2006                 Assistant Professor                   Internal Medicine/Nephrology                                NYUSOM, NY, NY
  13                               2015                  2008                 Assistant Professor                   Internal Medicine/Cardiology                                NYUSOM, NY, NY
  Post-Doctoral PhDs                                                                                                                                                            
  Index                            Year Received Award   Year of Graduation   Position                              Department                                                  Institution
  14                               2016                  2013                 Senior Manager                        Field Analytics & Operations                                Genentech, San Francisco, CA
  15                               2016                  2014                 Post-Doctoral PhD                     Basic Science and Craniofacial Biology                      NYU Dental School, NY, NY
  16                               2016                  1999                 Post-Doctoral PhD                     Microbiology                                                NYUSOM, NY, NY
  17                               2017                  2014                 Post-Doctoral PhD                     Pathology                                                   NYUSOM, NY, NY
  18                               2017                  2013                 Post-Doctoral PhD                     Endocrinology                                               NYUSOM, NY, NY
  19                               2017                  2016                 Post-Doctoral PhD                     Cell Biology                                                NYUSOM, NY, NY
  20                               2017                  2010                 Post-Doctoral PhD                     Microbiology                                                NYUSOM, NY, NY

Abbreviation: School of Medicine (SOM)
